By Maxx Chatsko
June 16, 2013
The Food and Drug Administration recently granted Gilead Sciences (NASDAQ: GILD ) priority review for its much-awaited hepatitis C drug sofosbuvir. Current treatments are far from perfect for the 3.2 million people suffering from chronic forms of the disease. This novel oral therapy has a lot going for it, which has some analysts thinking it could potentially hit $5 billion in peak sales. In the following video, Fool contributor Maxx Chatsko explains how Gilead's drug raises the bar for the future of hepatitis C treatment.
As mentioned in the video, AbbVie is also developing a next generation drug for hepatitis C. It has shown tremendous promise in clinical trials, but will it be enough once the company's golden goose, Humira, is cooked? The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
No comments:
Post a Comment